Pages that link to "Q88874526"
Jump to navigation
Jump to search
The following pages link to Susan E Bates (Q88874526):
Displaying 50 items.
- Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy (Q24609974) (← links)
- Multidrug resistance in cancer: role of ATP-dependent transporters (Q28208049) (← links)
- Mitotane Enhances Cytotoxicity of Chemotherapy in Cell Lines Expressing a Multidrug Resistance Gene (mdr-1/P-Glycoprotein) which is also Expressed by Adrenocortical Carcinomas (Q28322699) (← links)
- Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells (Q28377928) (← links)
- Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines (Q28483816) (← links)
- Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin (Q28611369) (← links)
- Cardiac involvement with lymphoma: a review of the literature (Q30478285) (← links)
- Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data (Q30936712) (← links)
- Clinical Toxicities of Histone Deacetylase Inhibitors (Q31135325) (← links)
- Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes (Q31932176) (← links)
- An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain (Q31936637) (← links)
- Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells (Q32016277) (← links)
- Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. (Q33194953) (← links)
- A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. (Q33201666) (← links)
- Single nucleotide polymorphisms modify the transporter activity of ABCG2. (Q33214177) (← links)
- A high-throughput cell-based assay for inhibitors of ABCG2 activity (Q33234390) (← links)
- Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization (Q33240063) (← links)
- Side population analysis using a violet-excited cell-permeable DNA binding dye. (Q33267436) (← links)
- Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. (Q33285468) (← links)
- New inhibitors of ABCG2 identified by high-throughput screening (Q33311099) (← links)
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms (Q33341474) (← links)
- Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data (Q33374219) (← links)
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma (Q33386623) (← links)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. (Q33390876) (← links)
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (Q33394324) (← links)
- A phase i study of DMS612, a novel bifunctional alkylating agent (Q33419113) (← links)
- Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. (Q33425469) (← links)
- Botryllamides: natural product inhibitors of ABCG2 (Q33474489) (← links)
- Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma (Q33510328) (← links)
- Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib (Q33566582) (← links)
- Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example (Q33567889) (← links)
- Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. (Q33718824) (← links)
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma (Q33726989) (← links)
- Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478 (Q33746958) (← links)
- The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. (Q33753716) (← links)
- Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells (Q33826871) (← links)
- Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs (Q33939126) (← links)
- Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. (Q34101040) (← links)
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy (Q34151732) (← links)
- PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer (Q34167479) (← links)
- Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter (Q34179757) (← links)
- Arginine 383 is a crucial residue in ABCG2 biogenesis (Q34180165) (← links)
- Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen (Q34218136) (← links)
- The Role of ABC Transporters in Clinical Practice (Q34268081) (← links)
- Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells (Q34297021) (← links)
- Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. (Q34385596) (← links)
- The role of half-transporters in multidrug resistance (Q34502464) (← links)
- A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. (Q34523239) (← links)
- Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene (Q34593947) (← links)
- New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies (Q34683488) (← links)